MARKET REPORT: Sirius Minerals soars on hopes of securing a £2.5bn funding deal 

As crunch time approaches for Sirius Minerals, the fertiliser company boring a massive tunnel underneath the North York Moors, investors have been eagerly snapping up its shares.

Sirius is trying to thrash out a financing agreement worth more than £2.5billion with an unnamed major financial institution, which should secure the construction of its Yorkshire polyhalite mine.

Though the firm is unlikely to announce any progress on whether it has secured a deal with the new lender before the end of April, the market is already getting excited.

Sirius Minerals is trying to thrash out a financing agreement worth more than £2.5billion with an unnamed major financial institution to fund its North Yorkshire fertiliser mine

The new cash should allow Sirius, which is a favourite with retail investors, the opportunity to turn its hole in the ground into a functional fertiliser mine and remove most of the risk from the project.

 

Shares shot up 5.5 per cent, or 1.22p, to 23.3p yesterday, – even as US conglomerate The Capital Group Companies, a major shareholder, revealed it had sold down a stake worth around £22million on Friday.

Such a large sale would usually flood the market, pushing down their price, but instead the stock has been eagerly snapped up.

The FTSE 100 ended the day in the red – down 0.35 per cent, or 26.32 points, at 7425.57 – as little news came from Theresa May’s talks in Berlin with German Chancellor Angela Merkel.

Packaging heavyweight Smurfit Kappa pulled the FTSE 100 down, falling 3.9 per cent, or 91p, to 2275p. 

Stock Watch -Shearwater 

Cyber security company Shearwater staged a mini recovery as it announced a deal to acquire assets from rival Secarma for £7.4million.

The new units will focus on testing how attackers can exploit businesses’ online operations, analysing and monitoring threats, and deliberately hacking systems to find weaknesses.

Chairman David Williams said Shearwater had seen rising demand for these particular types of services. Shares rose 14.6 per cent, or 0.2p, to 1.57p.

Travel company Tui was close behind, just days after it released a profit warning prompted by the grounding of Boeing’s 737 Max planes, dipping again by 3.1 per cent, or 23p, to 715.8p.

Investors in drugs giant Glaxosmithkline were largely unmoved by US medical regulators’ approval of a new HIV treatment, created by GSK and Pfizer.

The drug, Dovato, is the first ever once-daily single tablet containing two drugs, rather than three, to help treat HIV. GSK’s shares edged down 0.4 per cent, or 6p, to 1582.2p, suggesting investors were largely expecting the approval.

Fund manager Neil Woodford was able to provide investors with some cheer, as Reneuron – a company which he owns 35.5 per cent of – shot up by 29.8 per cent, or 51p, to 222p.

The firm is developing new types of stem cell treatments for diseases such as blindness-causing retinitis pigmentosa, and revealed it was licensing the rights to some of its programmes to Chinese pharmaceutical giant Fosun.

In return, it will be paid up to £80million if all milestones are met. Though Reneuron accounts for 0.9 per cent of the stock market-listed Woodford Patient Capital Trust, the trust’s shares slipped 0.4 per cent, or 0.3p, to 82.3p.

Meanwhile N4 Pharma, another specialist pharmaceutical company which is developing a new way to deliver vaccines and cancer treatments to patients, crashed 43.1 per cent, or 3.45p, to 4.55p.

The results of its tests with the University of Adelaide have so far not been positive and its Nuvec treatment has not been effective on living organisms.

Model train company Hornby, which has been trying to put issues surrounding late orders and lack of stock behind it for over a year, came further off the rails as it conceded revenue for the year ending March 2019 was still lower than the previous 12 months. 

The company said it was progressing with its turnaround, but the shares fell 4.1 per cent, or 1.5p, to 34.8p.

There was little fun to be had among the stock market’s gaming companies. Video games developer Sumo Group fell 4.2 per cent, or 6p, to 137p, despite growing revenues and profitability.

Meanwhile Stride Gaming, which develops online bingo and fruit machine games, slumped 8.9 per cent, or 11.5p, to 117p, as it warned regulatory changes would push revenues down 5 per cent.

 

Some links in this article may be affiliate links. If you click on them we may earn a small commission. That helps us fund This Is Money, and keep it free to use. We do not write articles to promote products. We do not allow any commercial relationship to affect our editorial independence.